Cogstate (ASX:CGS) Is Experiencing Growth In Returns On Capital
Cogstate Ltd Announces Share Buy-Back Update
Enrolment Completed in Actinogen's XanaCIDD Phase 2a Cognition & Depression Trial
Trial results anticipated in early Q3 this year SYDNEY, April 22, 2024 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces the full enrolment of 167 participants in the Company's XanaCIDD
Cogstate Ltd Continues Share Buy-Back Initiative
First Patient Treated in Actinogen's XanaMIA Phase 2b Alzheimer's Disease Trial
Plus, Actinogen receives approval of its application for a UK Innovation Passport as part of the Innovative Licensing and Access Pathway (ILAP) for Xanamem in the treatment of Alzheimer's disease Enr
Cogstate Ltd Continues Share Buy-Back Program
Cogstate (ASX:CGS) Shareholders Have Earned a 42% CAGR Over the Last Five Years
Cogstate Continues Aggressive Share Buy-Back
Cogstate Ltd Continues Share Buy-Back Effort
Cogstate Ltd Options Cease Amid Unmet Conditions
Cogstate Ltd Seeks Quotation for New Securities
Cogstate Continues Share Buy-Back Initiative
Cogstate Amends License Agreement With Eisai for Alzheimer's Treatment
Cogstate (ASX:CGS) has amended its global license agreement with Eisai Co. Ltd. to re-acquire rights to a technology that would allow it to build an integrated system for Alzheimer's treatment, accord
Do Cogstate's (ASX:CGS) Earnings Warrant Your Attention?
Cogstate Limited (ASX:CGS) Insiders Have Significant Skin in the Game With 50% Ownership
Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8%
Shares of Cogstate (ASX:CGS) declined nearly 8% in recent trade despite the company reporting Thursday that the net attributable profit after tax in the six-month period ended Dec. 31, 2023, grew to $
Are Cogstate Limited's (ASX:CGS) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Bullish Cogstate Insiders Loaded Up On US$4.47m Of Stock
Cogstate Ends Share Buyback Program
Cogstate (ASX:CGS) ended its share buyback program first disclosed last Feb. 23 as it enters a prohibited period as outlined in its share trading policy. Since the program began, the neurological asse
Investing in Cogstate (ASX:CGS) Five Years Ago Would Have Delivered You a 121% Gain
No Data